DarioHealth - DRIO Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DRIO shares.
View DRIO analyst ratings or view top-rated stocks.

4 analysts have issued 1 year target prices for DarioHealth's shares. Their DRIO share price forecasts range from $8.75 to $15.00. On average, they anticipate the company's share price to reach $12.94 in the next twelve months. This suggests a possible upside of 215.5% from the stock's current price.
View analysts price targets for DRIO or view top-rated stocks among Wall Street analysts.

DarioHealth's stock was trading at $12.97 at the beginning of 2022. Since then, DRIO stock has decreased by 68.4% and is now trading at $4.10.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our DRIO earnings forecast.

DarioHealth Corp. (NASDAQ:DRIO) issued its earnings results on Monday, August, 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.03. The firm had revenue of $6.18 million for the quarter, compared to the consensus estimate of $8.27 million. DarioHealth had a negative trailing twelve-month return on equity of 77.24% and a negative net margin of 301.07%. During the same period in the previous year, the business earned ($0.99) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."

DarioHealth's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (7.57%), Clal Insurance Enterprises Holdings Ltd (6.80%), Collaborative Holdings Management LP (5.34%), Millennium Management LLC (2.14%), MAI Capital Management (1.52%) and Renaissance Technologies LLC (0.42%). Insiders that own company stock include Adam K Stern, Dennis M Mcgrath, Dror Bacher, Erez Raphael and Oded Cohen.
View institutional ownership trends.

Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DRIO stock can currently be purchased for approximately $4.10.

DarioHealth (NASDAQ:DRIO) has a market capitalization of $94.21 million and generates $20.51 million in revenue each year. The company earns $-76,760,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.

The company employs 200 workers across the globe.

DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The official website for the company is www.mydario.com. The company can be reached via phone at (833) 914-3796, via email at ir@mydario.com, or via fax at 972-4770-4059.